萘莫司他抗凝在连续性肾脏替代治疗中应用的研究进展  

Research progress on the application of nafamostat anticoagulation in continuous renal replacement therapy

作　　者：周芯蕊 沈清[1] Zhou Xinrui;Shen Qing(Department of Nephropathy,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院肾脏内科,重庆400016

出　　处：《中国医药》2024年第8期1263-1266,共4页China Medicine

摘　　要：连续性肾脏替代治疗(CRRT)是一种广泛应用的体外循环血液净化技术,体外循环回路凝血是其常见并发症之一。临床上常使用肝素作为循环抗凝剂,但较高的出血风险使得该方案并不适用于凝血功能异常的患者。萘莫司他抗凝作用强,出血风险较小,更适合应用于具有高出血风险的患者。本文对萘莫司他在CRRT中的临床研究进展进行综述,以期能够为CRRT抗凝剂的选择提供一定的参考价值。Continuous renal replacement therapy(CRRT)is a widely used blood purification technique in extracorporeal circulation,and coagulation in the extracorporeal circulation circuit is one of its common complications.Heparin is commonly used as a circulating anticoagulant in clinical practice,but the higher risk of bleeding makes this regimen not suitable for patients with abnormal coagulation function.Nafamostat has a strong anticoagulant effect and a low risk of bleeding,which is more suitable for patients with high bleeding risk.This article reviews the clinical research progress of nafamostat in CRRT,in order to provide some reference value for the selection of anticoagulants for CRRT.

关 键 词：连续性肾脏替代治疗 萘莫司他 抗凝剂 

分 类 号：R459.5[医药卫生—治疗学]